Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and“AECOPD Risk-Window”: a randomised placebo-controlled study

Therapeutic effect evaluation of sequential treatment with syndrome differentiation for AECOPD

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001460

Enrollment

Unknown

Registered

2011-07-29

Start date

2011-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

contral group:Conventional treatment+traditional Chinese medicine simulants

experimental group:Conventional treatment+ traditional Chinese medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet with the diagnostic standard of acute exacerbation of chronic obstructive pulmonary disease, moderate or severe patients; 2. Aged between 40 and 80 years; 3. Syndrome differentiation belongs to Syndrome of exogenous cold-evil and internalization Syndrome of accumulation of phlegm-dampness in the lung, Syndrome of phlegm-heat obstructing in the lung; 4. Without participations in other interventional trials in the previous one month; 5. With the informed consent signed.

Exclusion criteria

Exclusion criteria: (1) Pregnant or breast-feeding women; (2) Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study; (3) Complicated with severe heart failure (class IV NYHA heart function) or unstable hemodynamics; (4) Complicated with bronchial asthma, bronchiectasis or active tuberculosis; (5) Complicated with obliterative bronchiolitis or diffuse pantothcnic bronchiolitis; (6) Complicated with pneumothorax, pleural effusion or pulmonary embolism; (7) Complicated with neuromuscular disorder which affects the respiration; (8) Complicated with tumors; (9) Complicated with respiratory failure subjects that needs mechanical ventilation; (10) Complicated with serious hepatic and renal diseases; (11) Long periods of bed rest; (12) With immunodeficiency; (13) Participating in other trials or allergic to the used medicine.

Design outcomes

Primary

Measure	Time frame
excerbations;dyspnea;Clinical symptoms and sign;	—

Secondary

Measure	Time frame
quality of life;dorctor report outcome;degree of satisfaction;pulmonary function;mortality rate;patient report outcom;	—

Countries

China

Contacts

Public ContactLi Jiansheng

li_js8@163.com+86 0371 65676568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 26, 2026